Onkologie. 2016:10(2):76-78 | DOI: 10.36290/xon.2016.018

Axtinib in treatment metastatic renal cell carcinoma

Igor Richter¹, Josef Dvořák², Věra Hejzlarová¹, Jiří Bartoš¹

¹ Onkologické oddělení, Krajská nemocnice Liberec, Liberec

² Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Aim: A retrospective evaluation of efficacy and toleration of axitinib.

Patients and methods: A total of 11 patients with metastatic renal cell carcinoma previously treated by sunitinib were evaluated.

Axitinib was applied in doses 10 mg/kg twice a day. Response rate was evaluated by RECIST 1.1. We defined two parameters:

overall survival (OS) and progression free survival (PFS).

Results: We described the toxicity in all patiens, predominantly grade I-II. Three patiens were hospitalized. One patiens died of

hemoptysis. We did not described the complete remission, partial remission we desribed in 3 patients (27.2 %) and stabilization

in 5 patients (45.5 %). Primary progression we finded in 3 patients (27.2 %). The median of PFS was 13.9 months (95 % CI 4.2–14.9

měsíce). Median of OS was not reached. 1-year OS we desribed in 59 % of patiens.

Conclusion: The treatment with axitinib we evaluate positively. Axitinib is integral part of treatment in patiens with metastatic

renal cell carcinoma.

Keywords: renal cell carcinoma, targeted treatment, axitinib, overall survival, progression free survival

Published: May 1, 2016  Show citation